Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han-Shen Tae

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
FASEB Bioadvances|March 4, 2020
Drysdalin, an antagonist of nicotinic acetylcholine receptors highlights the importance of functional rather than structural conservation of amino acid residuesRitu Chandna, Han-Shen Tae, Victoria A L Seymour, et al.
British Journal of Pharmacology|May 8, 2019
Molecular dynamics simulations of dihydro-β-erythroidine bound to the human α4β2 nicotinic acetylcholine receptorRilei Yu, Han-Shen Tae, Qingliang Xu, et al.
Marine Drugs|March 27, 2024
Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine ReceptorsTianmiao Li, Han-Shen Tae, Jiazhen Liang, et al.
Marine Drugs|June 8, 2017
A Novel Lid-Covering Peptide Inhibitor of Nicotinic Acetylcholine Receptors Derived from αD-Conotoxin GeXXALongjin Yang, Han-Shen Tae, Zhou Fan, et al.
Neuropharmacology|June 17, 2020
Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and Ca<sub>V</sub>2.2 channelsHugo R Arias, Han-Shen Tae, Laura Micheli, et al.
Biochemical Pharmacology|April 5, 2024
Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABA<sub>A</sub> receptor and Ca<sub>V</sub>2.2 channelHan-Shen Tae, Marcelo O Ortells, Arsalan Yousuf, et al.
Clinical and Experimental Pharmacology & Physiology|December 17, 2008
Molecular recognition of the disordered dihydropyridine receptor II-III loop by a conserved spry domain of the type 1 ryanodine receptorHan-Shen Tae, Nicole C Norris, Yanfang Cui, et al.
Journal of Medicinal Chemistry|September 22, 2022
Mechanism of Action and Structure-Activity Relationship of α-Conotoxin Mr1.1 at the Human α9α10 Nicotinic Acetylcholine ReceptorJiazhen Liang, Han-Shen Tae, Zitong Zhao, et al.
ACS Chemical Neuroscience|December 17, 2025
Isodrimenine Derivatives Selectively Inhibit Human α7-Containing Nicotinic Acetylcholine Receptors via Negative Allosteric ModulationHan-Shen Tae, Marcelo O Ortells, Alexandru Ciocarlan, et al.
Journal of Medicinal Chemistry|January 13, 2024
Dual Antagonism of α9α10 nAChR and GABA<sub>B</sub> Receptor-Coupled Ca<sub>V</sub>2.2 Channels by an Analgesic αO-Conotoxin AnalogueXiao Li, Han-Shen Tae, Shen Chen, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
FASEB Bioadvances|March 4, 2020
Drysdalin, an antagonist of nicotinic acetylcholine receptors highlights the importance of functional rather than structural conservation of amino acid residuesRitu Chandna, Han-Shen Tae, Victoria A L Seymour, et al.
British Journal of Pharmacology|May 8, 2019
Molecular dynamics simulations of dihydro-β-erythroidine bound to the human α4β2 nicotinic acetylcholine receptorRilei Yu, Han-Shen Tae, Qingliang Xu, et al.
Marine Drugs|March 27, 2024
Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine ReceptorsTianmiao Li, Han-Shen Tae, Jiazhen Liang, et al.
Marine Drugs|June 8, 2017
A Novel Lid-Covering Peptide Inhibitor of Nicotinic Acetylcholine Receptors Derived from αD-Conotoxin GeXXALongjin Yang, Han-Shen Tae, Zhou Fan, et al.
Neuropharmacology|June 17, 2020
Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and Ca<sub>V</sub>2.2 channelsHugo R Arias, Han-Shen Tae, Laura Micheli, et al.
Biochemical Pharmacology|April 5, 2024
Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABA<sub>A</sub> receptor and Ca<sub>V</sub>2.2 channelHan-Shen Tae, Marcelo O Ortells, Arsalan Yousuf, et al.
Clinical and Experimental Pharmacology & Physiology|December 17, 2008
Molecular recognition of the disordered dihydropyridine receptor II-III loop by a conserved spry domain of the type 1 ryanodine receptorHan-Shen Tae, Nicole C Norris, Yanfang Cui, et al.
Journal of Medicinal Chemistry|September 22, 2022
Mechanism of Action and Structure-Activity Relationship of α-Conotoxin Mr1.1 at the Human α9α10 Nicotinic Acetylcholine ReceptorJiazhen Liang, Han-Shen Tae, Zitong Zhao, et al.
ACS Chemical Neuroscience|December 17, 2025
Isodrimenine Derivatives Selectively Inhibit Human α7-Containing Nicotinic Acetylcholine Receptors via Negative Allosteric ModulationHan-Shen Tae, Marcelo O Ortells, Alexandru Ciocarlan, et al.
Journal of Medicinal Chemistry|January 13, 2024
Dual Antagonism of α9α10 nAChR and GABA<sub>B</sub> Receptor-Coupled Ca<sub>V</sub>2.2 Channels by an Analgesic αO-Conotoxin AnalogueXiao Li, Han-Shen Tae, Shen Chen, et al.
Pageof 6